Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1273636/000119312519139735/d736075d10q.htm
August 2022
July 2022
June 2022
May 2022
May 2022
March 2022
March 2022
February 2022
February 2022
January 2022
Exhibit 99.1
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 7, 2019 Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2019.
Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansion cohort of our Phase 1/2 trial in patients with X-linked retinitis pigmentosa demonstrates our clinical development progress and keeps us on track to report multiple data sets in the second half of 2019, said Sue Washer, President and CEO of AGTC. Achieving these clinical milestones reflects our continued progress and commitment to developing new approaches to treat inherited retinal diseases positioning AGTC well to create value for patients and shareholders.
AGTC Clinical Program Update
AGTC remains on track to meet its current enrollment milestones across its three Phase 1/2 clinical programs:
X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Clinical Trial
To date, AGTC has completed enrollment of ten patients in the dose escalation portion of the XLRP trial and six patients in the expansion portion of the trial. The Company expects to:
| Provide interim six-month data for the dose escalation group in the third quarter of 2019; and |
| Provide interim six-month data for the expansion group in the fourth quarter of 2019. |
Achromatopsia (ACHM) Phase 1/2 Clinical Trials
The Company is enrolling patients in two parallel Phase 1/2 clinical trials of its product candidates for ACHM caused by mutations in the two most common ACHM genes, CNGB3 and CNGA3. To date, AGTC has enrolled twelve patients in the ACHM CNGB3 trial and seven patients in the ACHM CNGA3 trial. The Company expects to:
| Complete enrollment of the dose escalation portion of the CNGA3 trial in the second quarter of 2019; |
1
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1273636/000119312519139735/d736075d10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Applied Genetic Technologies Corp.
Applied Genetic Technologies Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
We do not allocate personnel-related costs, including stock-based compensation, costs associated with broad technology platform improvements or other indirect costs, to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as internal research and development expenses in the table above.
The increase in license and related services revenue was primarily due to recognizing revenue of $18.0 million as result of the termination of the Collaboration Agreement with Biogen effective March 8, 2019, partially offset by decreased license and related service revenue, when excluding amounts recognized upon the termination of the Collaboration Agreement, due to the Companys revised pattern of revenue recognition under ASC 606.
The decrease was primarily driven by lower employee-related costs and share-based based compensation of $0.3 million and lower other general and administrative expenses of $0.7 million attributable to decrease in bad debt expense and other administrative expenses incurred during normal business operation.
General and administrative expense General and administrative expense for the three months ended March 31, 2019 decreased by $0.8 million to $3.1 million compared to the same period in 2018.
General and administrative expense General and administrative expense for the nine months ended March 31, 2019 decreased by $1.7 million to $9.3 million compared to the same period in 2018.
The increase was primarily due...Read more
The decrease was primarily driven...Read more
The increase was primarily due...Read more
Since our inception in 1999,...Read more
Research and development expenses for...Read more
Factors that could cause or...Read more
Upon the termination of the...Read more
For a description of our...Read more
Accordingly, we expect that our...Read more
The increase in internal spending...Read more
The increase in development services...Read more
Other general and administrative expenses...Read more
Except as required by law,...Read more
Forward-looking statements include all statements...Read more
On December 7, 2018, we...Read more
The increase in milestone revenue...Read more
We expect our research and...Read more
23 Research and development expense...Read more
Costs for certain development activities...Read more
Research and development expenses Research...Read more
Thereafter, no additional collaboration revenue...Read more
We have incurred cumulative losses...Read more
We believe that our existing...Read more
We believe that our existing...Read more
Provision for income taxes Income...Read more
We expect to continue to...Read more
21 Revenue We primarily generate...Read more
The income tax expense for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Applied Genetic Technologies Corp provided additional information to their SEC Filing as exhibits
Ticker: AGTC
CIK: 1273636
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-19-139735
Submitted to the SEC: Tue May 07 2019 12:33:07 PM EST
Accepted by the SEC: Tue May 07 2019
Period: Sunday, March 31, 2019
Industry: Biological Products No Disgnostic Substances